ArticleJournal of neuro-oncology2025
Repeated stereotactic radiosurgery for high grade meningioma.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesAtypical and anaplastic meningioma (World Health organization [WHO] Grades II and III) present therapeutic challenges due to their aggressive behavior and high risk of recurrence. This study addressed the lack of data related to the effectiveness and safety of repeated stereotactic radiosurgery (SRS) in managing high-grade recurrent or residual meningioma.
methodsThis study analyzed data extracted from the medical records of 112 patients (mean age of 57.9 years) who underwent SRS for recurrent or residual high-grade meningioma between January 2002 and December 2022. The data included clinicodemographic profiles, treatment parameters, and imaging phenotypes. The average follow-up duration was 41.7 months (range 12-160.7 months).
resultsThere was slight preponderance of females in the cohort (65:47). All patients had undergone craniotomy and histopathologic confirmation of atypical or anaplastic meningioma. Gross tumor resection was achieved in 35 cases. Atypical meningioma accounted for the vast majority of cases (105; 93.8%) with only 7 cases of anaplastic meningioma (6.2%). At a median follow-up of 41.7 months after SRS, tumor control was achieved in 29.5% of cases. Kaplan-Meier analysis indicated overall actuarial progression free survival rates of 79.5%, 43.8% and 30.4% at 1, 3 and 5 years after radiosurgery, respectively. In cases involving repeated SRS, these rates were 97.6%, 69% and 45.2%, respectively. Male sex, older age, anaplastic phenotype, subtotal resection, and larger tumor volume were significantly predictive of tumor growth after treatment. Adverse radiation effects were observed in 33.8% of patients who underwent repeated SRS. Most of those patients were asymptomatic and only five patients required a temporary course of steroid therapy.
conclusionsOur data suggest that SRS is a relatively safe and effective treatment option for recurrent or residual high-grade meningioma, with an acceptable complication profile, even when performed repeatedly. Anaplastic tumor phenotype, subtotal resection, and larger tumor volume were factors associated with tumor growth, warranting close clinical surveillance after radiosurgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.